Phase 3 Lung Cancer Trial, Recruiting NCT04322617 Sponsor: Hunan Province Tumor Hospital Condition: Lung Cancer
Back to Lung Cancer

Phase 3 Lung Cancer Trial, Recruiting

NCT04322617
Recruiting Phase 3

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who understand what the trial involves and are willing to sign a consent form agreeing to take part.
  • People aged 18 or older.
  • People who have been diagnosed with lung cancer confirmed by a tissue or cell sample test.
  • People whose lung cancer has stopped responding to a first course of treatment combining chemotherapy and immunotherapy.
  • People who are relatively well and able to carry out daily activities with little or no restriction (this is measured using a standard scale called ECOG, scored 0 or 1).
  • People whose doctors expect them to survive for at least 12 weeks.
  • People whose blood counts and organ function (such as kidneys and liver) are at adequate levels (confirm with trial site).
  • People who have at least one measurable tumour that can be tracked using standard imaging guidelines (confirm with trial site).
  • People who have brain metastases (cancer that has spread to the brain) that are considered stable may also be considered.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have received certain targeted cancer treatments (such as EGFR or VEGFR antibody therapies) within the 4 weeks before starting the trial.
  • People who have had radiation therapy within 14 days before starting the trial, or who are still recovering from side effects of radiation (some specific types of radiotherapy may be acceptable if completed at least 7 days before starting).
  • People who are taking, or cannot stop taking, certain medications or herbal supplements that strongly affect how the body processes drugs (known as CYP1A2 or CYP3A inhibitors or inducers) within 1 to 2 weeks before starting the trial (confirm specific medications with trial site).
  • People who have cancer that has spread to compress the spinal cord, or cancer that has spread to the membranes surrounding the brain or spinal cord.
  • People who have had another type of cancer within the past 2 years.
  • People who still have significant side effects (other than hair loss) from previous cancer treatments at the time of starting the trial.
  • People who have had a stroke or bleeding in the brain within the 6 months before starting the trial.
  • People with serious or poorly managed health conditions, including poorly controlled high blood pressure or active bleeding.
  • People with ongoing or active infections, including hepatitis B, hepatitis C, HIV, or COVID-19.
  • People with certain heart-related conditions or abnormalities (confirm specific details with trial site).
  • People who have a history of serious lung inflammation conditions, including certain types of interstitial lung disease or immune-related lung problems caused by previous immunotherapy.
  • People who have severe nausea, vomiting, chronic gut disease, difficulty swallowing, or who have had bowel surgery that may prevent the study medications from being properly absorbed.
  • People who have received a live vaccine within 2 weeks before starting the trial.
  • Women who are pregnant or breastfeeding.
  • People who have a known allergy or sensitivity to the trial drugs or their ingredients.
  • People whom the trial doctors consider unsuitable for participation for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026

Contact this trial

Principal Investigator: Yongchang Zhang, MD, Hunan Cancer Hospital

Phone: +8613873123436

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Hunan Province Tumor Hospital
Registry
ClinicalTrials.gov
Start date
24 March 2020
Est. completion
24 March 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression free survival time (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov